TrialJournal for immunotherapy of cancer2025

Bevacizumab, tislelizumab and nab-paclitaxel for previously untreated metastatic triple-negative breast cancer: a phase II trial.

Meiting Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.